ClinicalTrials.gg
CompletedNCT02049450Updated Jul 17, 2017Results posted

Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.

A Phase 2 interventional study of ruxolitinib in Thalassemia Major, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in beta-Thalassemia by Novartis — none open to participants now, none under way, none of them phase 3. beta-Thalassemia · Novartis.

Enrollment
8th of 11
30 · median 166
Started
2014
the only one that year
Phase 2
4 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in beta-Thalassemia by Novartis, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 2, and was the 11th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

None of the 11 studies in beta-Thalassemia by Novartis is open now. The open studies under beta-Thalassemia, anywhere →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in beta-Thalassemia by Novartis as a file.
02

Study summary

Patients with severe thalassemia (thalassemia major) present with severe anemia that required life-long transfusion therapy, spleen enlargement that led to increased transfusion requirement, and other serious complications as early death, growth retardation, bone deformations and iron overload due to blood transfusions. Splenectomy can significantly reduce transfusion requirement in thalassemia patients, but it is associated with an increased risk of serious complications such as sepsis and thrombosis. Preliminary preclinical and clinical data suggested that JAK2 inhibition, by reducing spleen size, could improve hemoglobin levels, thereby eliminating the need for splenectomy and reducing transfusion requirement and related iron overload.

03

Conditions studied

  • Thalassemia Major

Keywords

  • thalassemia
  • thalassemia major
  • spleen enlargement
  • INC424
  • ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with thalassemia on a regular and stable transfusion regimen (at least 2 RBC units within every 4-week interval for 24 weeks prior to Screening) and anticipated to receive the same transfusion regimen during the study.
  • Patients with spleen enlargement at Screening, defined as spleen palpable below the costal margin and spleen volume of ≥ 450 cm3 as confirmed by MRI (or CT scan in applicable patients).
  • Patients need to be on iron chelation treatment (deferoxamine or deferasirox) for at least four weeks prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Splenectomy prior to or planned during the study
  • Active serious bacterial, mycobacterial, fungal, parasitic or viral infection which requires therapy (e.g., pneumonia, tuberculosis, systemic mycosis, herpes zoster)
  • \<65 g/L (\<4.0 mmol/L) at Screening
  • count \<75×109/L, absolute neutrophils count \< 1.5×109/L at Screening.
  • Estimated \< 30 mL/min/1.73 m2 at Screening.
  • (SGPT) levels >5 times at Screening.
  • Hepatocellular disease such as (presence of HBs antigen), (presence of HCV RNA), liver cirrhosis.
  • positivity
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    INC424 (ruxolitinib) - Study Treatment

    Regularly transfused adult patients with thalassemia and spleen enlargement.

    Drug: ruxolitinib

Interventions

  • Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.

    Also known as: INC424

06

What researchers measure

Primary outcomes

  1. Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC)

    Change of RBC transfusion requirement measured as percent change of the hematocrit-adjusted volume of transfused RBC and observed during within on-treatment interval (any time-points of RBC transfusion between week 6 and week 30 driven by the individual patient's need) compared to baseline (defined by pre-treatment interval between Week - 24 to start of treatment).

    Time frame: week 6 to week 30 interval

Secondary outcomes

  1. Percentage Change in Spleen Volume (cm3)

    Change of spleen volume from baseline at week 12 and week 30 as measured by magnetic imaging resonance (MRI) or computed tomography (CT).

    Time frame: baseline, week 12, week 30

  2. Percentage Change in Mean Pre-transfusion Hemoglobin by 6 Week Time Intervals

    Change from baseline in pre-transfusion hemoglobin levels

    Time frame: baseline, weeks 0 - 30

  3. Percentage Change in Spleen Length (cm) Below the Left Coastal Margin

    Change of spleen length from baseline over time measured by palpitation by time

    Time frame: baseline, weeks 1,2,3,4,6,12,18,24,30

  4. Pharmacokinetics (PK) Parameter of Cmin

    C min of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 15 (Week 2), and Day 85 (Week 12). Cmin was collected immediately prior to dosing. n= number of patients with valid PK samples as per definition of the PK analysis set.

    Time frame: week 2, week 12

  5. Pharmacokinetics (PK) Parameter of Cmax

    Cmax (1h) of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 1, Week 2, and Week 12. Cmax was collected within a +/- 1 hour post dose. n= number of patients with valid PK samples as per definition of the PK analysis set.

    Time frame: Day 1, Week 2 (Day 15), Week 12 (Day 85)

07

Results

Posted Jun 15, 2017

Participant flow

Participant flow — Overall Study
MilestoneINC424 (Ruxolitinib) - Study Treatment
Started30
Discontinued treatment prior to week 304
Entered extension phase18
Completed26
Not completed4
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Withdrew: Patients/guardian decision1

Outcome measures

PrimaryChange of Hematocrit Adjusted Volume of Red Blood Cells (RBC)

Change of RBC transfusion requirement measured as percent change of the hematocrit-adjusted volume of transfused RBC and observed during within on-treatment interval (any time-points of RBC transfusion between week 6 and week 30 driven by the individual patient's need) compared to baseline (defined by pre-treatment interval between Week - 24 to start of treatment).

Time frame:
week 6 to week 30 interval
Reported as:
Mean · % change of hematocrit-adjusted volume
Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC)
% change of hematocrit-adjusted volumeINC424 (Ruxolitinib) - Study Treatment
Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC)-5.934 ± 22.1681
SecondaryPercentage Change in Spleen Volume (cm3)

Change of spleen volume from baseline at week 12 and week 30 as measured by magnetic imaging resonance (MRI) or computed tomography (CT).

Time frame:
baseline, week 12, week 30
Reported as:
Mean · percentage change
Percentage Change in Spleen Volume (cm3)
percentage changeINC424 (Ruxolitinib) - Study Treatment
% change from baseline at Week 12-19.733 ± 16.0539
% change from baseline at Week 30-26.829 ± 16.6936
SecondaryPercentage Change in Mean Pre-transfusion Hemoglobin by 6 Week Time Intervals

Change from baseline in pre-transfusion hemoglobin levels

Time frame:
baseline, weeks 0 - 30
Reported as:
Mean · percentage change of hemoglobin levels
Percentage Change in Mean Pre-transfusion Hemoglobin by 6 Week Time Intervals
percentage change of hemoglobin levelsINC424 (Ruxolitinib) - Study Treatment
Weeks 0 - 6 )0.43 ± 10.135
Weeks 6 - 122.87 ± 10.555
Weeks 12 - 182.78 ± 11.081
Weeks 18 - 24-0.56 ± 9.760
Weeks 24 - 300.06 ± 14.321
SecondaryPercentage Change in Spleen Length (cm) Below the Left Coastal Margin

Change of spleen length from baseline over time measured by palpitation by time

Time frame:
baseline, weeks 1,2,3,4,6,12,18,24,30
Reported as:
Mean · percentage change in spleen length
Percentage Change in Spleen Length (cm) Below the Left Coastal Margin
percentage change in spleen lengthINC424 (Ruxolitinib) - Study Treatment
Week 1-11.19 ± 15.376
Week 2-22.11 ± 23.604
Week 3-25.01 ± 24.178
Week 4-26.94 ± 25.343
Week 6-33.85 ± 25.251
Week 12-49.29 ± 26.792
Week 18-56.32 ± 29.994
Week 24-56.93 ± 29.552
Week 30-57.40 ± 36.970
SecondaryPharmacokinetics (PK) Parameter of Cmin

C min of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 15 (Week 2), and Day 85 (Week 12). Cmin was collected immediately prior to dosing. n= number of patients with valid PK samples as per definition of the PK analysis set.

Time frame:
week 2, week 12
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) Parameter of Cmin
ng/mL10 mg Bid15mg Bid20mg Bid
Week 2 (Day 15)7.5800 ± 7.57959NA ± NANA ± NA
Week 12 (Day 85)9.1300 ± 7.6103918.5400 ± 23.9994020.2300 ± 25.98617
SecondaryPharmacokinetics (PK) Parameter of Cmax

Cmax (1h) of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 1, Week 2, and Week 12. Cmax was collected within a +/- 1 hour post dose. n= number of patients with valid PK samples as per definition of the PK analysis set.

Time frame:
Day 1, Week 2 (Day 15), Week 12 (Day 85)
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) Parameter of Cmax
ng/mL5mg Bid10mg Bid15mg Bid20mg Bid
Day 158.2000 ± 0.00126.8000 ± 58.703370.00 ± 0.000.00 ± 0.00
Week 256.7000 ± 0.00125.400 ± 40.618050.00 ± 0.000.00 ± 0.00
Week 120.00 ± 0.00107.2100 ± 50.07525245.6900 ± 50.00362185.0000 ± 97.58074

Adverse events

Collected over Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INC424 (Ruxolitinib) - Study Treatment—6/30 (20%)23/30 (76.7%)
Most frequent serious events
Most frequent serious events
EventINC424 (Ruxolitinib) - Study Treatment
PneumoniaInfections and infestations2/30
AnaemiaBlood and lymphatic system disorders1/30
NauseaGastrointestinal disorders1/30
VomitingGastrointestinal disorders1/30
PyrexiaGeneral disorders1/30
Drug-induced liver injuryHepatobiliary disorders1/30
Pneumonia viralInfections and infestations1/30
Most frequent other events
Showing 10 of 22
Most frequent other events
EventINC424 (Ruxolitinib) - Study Treatment
Upper respiratory tract infectionInfections and infestations8/30
Abdominal pain upperGastrointestinal disorders5/30
DiarrhoeaGastrointestinal disorders5/30
NauseaGastrointestinal disorders5/30
Weight increasedInvestigations5/30
AnaemiaBlood and lymphatic system disorders4/30
Alanine aminotransferase increasedInvestigations4/30
FatigueGeneral disorders3/30
GastroenteritisInfections and infestations3/30
NasopharyngitisInfections and infestations3/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)INC424 (Ruxolitinib) - Study Treatment
Mean25.9 ± 6.83
Sex: Female, Male
Sex: Female, Male(Participants)INC424 (Ruxolitinib) - Study Treatment
Female12
Male18
08

Study locations

7 sites
  • Novartis Investigative Site
    Athens, GR GR-115 27, Greece
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Palermo, PA 90146, Italy
  • Novartis Investigative Site
    Beirut, 1107 2020, Lebanon
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Apr 2016, 22 months.

Results were first posted in Jun 2017, 1 year 2 months after primary completion.

Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2014
First posted
Jan 30, 2014
StartActual
May 28, 2014
Primary completionActual
Apr 12, 2016
CompletionActual
Apr 12, 2016
Results first posted
Jun 15, 2017
Last update
Jul 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02049450
Responsible party
Sponsor
First posted
Jan 30, 2014
Start date
May 28, 2014
Primary completion
Apr 12, 2016
Completion
Apr 12, 2016
Results posted
Jun 15, 2017
Last update
Jul 17, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion